A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs BL 8040 (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms BLAST
- 11 Aug 2017 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 17 Aug 2015 Status changed from not yet recruiting to recruiting according to a BioLineRx media release.